Korean J Med > Volume 71(1); 2006 > Article
The Korean Journal of Medicine 2006;71(1):181-181.
LV, 5FU with/without docetaxel in patients with inoperable or relapsed gastric cancer
, ,
가천의과대학교길병원
LV, 5FU with/without docetaxel in patients with inoperable or relapsed gastric cancer
Kwang-Sun Lee, Sang-Jae Lee, Joung-Soon Jang
.
Abstract
Purpose
To estimate the effect and toxicity of leucovorin(LV) and fluorouracil(5FU) with/without docetaxel(LV5FU2D/LV5FU2) combination chemotheraphy in patients with inoperable or postoperative relapsed gastric cancer. Methods Total 27 patients are enrolled in this study. 8 patients received LV 20mg/m2(bolus), 5FU 400mg/m2(bolus), 5FU 600mg/m2(24-hour continuous infusion) on day 1, 2, 15, and 16, every 4 weeks(LV5FU2). 19 patients received LV5FU2 plus docetaxel 60mg/m2(1-hour infusion) on day 15(LV5FU2D). Results A total of 17 cycles of LV5FU2 and 101 cycles of LV5FU2D were administered. Response is observed only in LV5FU2D group and the response rate were 40.0% with 2 complete response and 4 partial response in 15 evaluable LV5FU2D group patients. The median response duration is 183 days (95% CI, 57-183). As compared with LV5FU2 group, LV5FU2D had a higher likelihood of median time to progression (228 days (95% CI, 58-127) in LV5FU2D, 85 days (95% CI, 58-127) in LV5FU2; P<0.0001). The grade 3-4 toxcity of neutropenia(24.6%) is observed in LV5FU2D group and of neutropenia(5.7%), anemia(5.7%) is observed in LV5FU2 group. The grade 1 toxcity of injection site reaction is observed all patients and the grade 1-2 toxcity of alopecia is observed 60% in LV5FU2D group. Conclusion LV5FU2D significant increase response and time to progression in patients with inoperable or postoperative relapsed gastric cancer than LV5FU2, and is observed tolerable toxicity.


TOOLS
METRICS Graph View
  • 1,296 View
  • 0 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2026 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next